Botulinum Toxin and Burn Induces Contracture

 

 Permissions and Reprints

Scar formation is one of the physiological processes of wound healing in the deepest part of the damaged dermis [[1]]. Hypertrophic scars and keloids are formed as the muscles pull the edges of a wound while the collagen fibers of the skin are still immature [[2]]. Temporarily paralyzing the muscles around the wound with botulinum toxin is one of the newer methods used during the process of reconstructive surgery [[2]]. Botulinum toxin directly inhibits fibroblast-to-myofibroblast differentiation in vitro, and it is indicated for its potential use in the treatment of wounds after trauma, burn, or surgery [[3]]. However, based on the available information, it is difficult to predict the therapeutic response of scars to botulinum, and more studies are needed before this method can become a standard therapy. We studied the effectiveness of a botulinum toxin injection in the recovery rate of contractures, which was burn induced and did not recovery acceptably by the surgical reconstruction of scars.

This was a randomized, controlled clinical trial. Patients aged 2 to 50 years with a chronic burn scar with contracture in certain areas of the body include joints, palms , eyelids, lip and cheek, were enrolled in the study. The burn must have occurred at least three months before the intervention and it must have produced a red scar (an immature scar).

Exclusion criteria were the previous treatment of spasticity, known sensitivity to botulinum toxin, isease that affects muscles, or use of aminoglycoside antibiotics such as spectinomycin within a period 30 days before or during the study.

The participants were divided into two groups. One group received an injection of botulinum toxin and the second group was followed without any intervention.

In the adults we injected botulinum toxin as 100 Units of Botox into the center, around the periphery, and at the two ends of the lesion. The method of injection was meso injection, in which botulinum toxin was injected subdermally, intradermally and into the scar, diffusely.

In children under 15 years old, the dose was 50 Units of Botox and in the children under five, 25 units.

In palms, upper eyelid and the small joints such as fingers, the maximum dose was 10 units.

In the lower eyelid, lower lip, and cheek, 10–15, 15–20, and 10 units were injected, respectively.

All patients were followed for six months with the same schedule.

In the major joints, we used a plastic manual goniometer (Phoenix Healthcare Products, Nottingham, UK) to a precision of 1°. Range of motion was defined between 0° and 100°.

For eyelid contracture, scoring was defined as follows [[4]]: complete closing, 4; pupils not visible, 3; pupils visible, 2; and complete opening, 1.

Of the 50 subjects, eight were lost during the follow-up. The baseline characteristics of the lost subjects were same in the intervention and control groups.

We analyzed the data of the 42 remaining patients. Among them, 51% were male and 49% female.

The total mean±standard deviation of age was 20.5±10.8.

The sex and age distribution was similar in both groups (P>0.05).

The range of motion of contracted parts of the body before and after intervention is shown in [Table 1]. Before injection, the range of motion in the intervention group was 58±17.6, and in the control was 73.9±32.9 (P>0.05). After injection, it changed to 89.8±21.5 and 81±43.5, respectively. This means that the improvement was 43% greater in the botulinum toxin group. Although the intervention group had more contracture than the control group, the difference was not statistically significant. Although the range of motion improved in both groups, the change in the range of motion was significantly greater in the intervention group (30.9° vs. 7.1°, respectively).

The severity of eyelid contracture in the control group did not change, while in the intervention group, it improved but not significantly ([Table 1]) ([Fig. 1]).

[Fig. 2] shows scar changes before and 3 months and 5 months after injection of botulinum toxin.

Generally, botulinum toxin injections relaxed the scar tissue, then established blood flow; this mechanism enabled the process of remodeling [[5]].

This study showed that for the endpoint, there was no statistically significant difference between treatment groups. This seems to be due to the small sample size. Although burn-induced contracture decreased during the healing period even without any intervention, the study detected a change of 30.9° versus 7°, which was considered to be of clinical relevance and to represent a clinically meaningful improvement in functional gain.

Publication History

Received: 26 January 2015

Accepted: 16 March 2016

Article published online:
20 April 2022

© 2016. The Korean Society of Plastic and Reconstructive Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonCommercial License, permitting unrestricted noncommercial use, distribution, and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes. (https://creativecommons.org/licenses/by-nc/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

• References

• 1 Gauglitz GG. Therapeutic strategies for the improvement of scars. Prime 2012; 2: 16-27
  Google Scholar
• 2 Wilson AM. Use of botulinum toxin type A to prevent widening of facial scars. Plast Reconstr Surg 2006; 117: 1758-1766
  CrossrefPubMedGoogle Scholar
• 3 Jeong HS, Lee BH, Sung HM. et al. Effect of botulinum toxin type a on differentiation of fibroblasts derived from scar tissue. Plast Reconstr Surg 2015; 136: 171e-178e
  CrossrefPubMedGoogle Scholar
• 4 Malhotra R, Sheikh I, Dheansa B. The management of eyelid burns. Surv Ophthalmol 2009; 54: 356-371
  CrossrefPubMedGoogle Scholar
• 5 Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000; 38: 245-258
  CrossrefPubMedGoogle Scholar